A Phase I, Dose Escalation Study to Assess the Safety and Pharmacokinetics of SB- 485232 Administered as Daily Subcutaneous Injections in Adult Patients With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 15 Oct 2008
At a glance
- Drugs Iboctadekin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 15 Oct 2008 Actual start date (Jan 2003) added as reported by ClinicalTrials.gov.
- 15 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Jul 2008 Actual patient number (25) added as reported by ClinicalTrials.gov.